

Meri Rogava

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2545149/publications.pdf>

Version: 2024-02-01

13
papers

2,241
citations

933447

10
h-index

1058476

14
g-index

15
all docs

15
docs citations

15
times ranked

4645
citing authors

#	ARTICLE	IF	CITATIONS
1	Ultraviolet-radiation-induced inflammation promotes angiogenesis and metastasis in melanoma. <i>Nature</i> , 2014, 507, 109-113.	27.8	547
2	Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. <i>Nature</i> , 2012, 490, 412-416.	27.8	506
3	A molecular single-cell lung atlas of lethal COVID-19. <i>Nature</i> , 2021, 595, 114-119.	27.8	411
4	A single-cell landscape of high-grade serous ovarian cancer. <i>Nature Medicine</i> , 2020, 26, 1271-1279.	30.7	267
5	Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. <i>Immunity</i> , 2017, 47, 789-802.e9.	14.3	207
6	Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion. <i>Nature Genetics</i> , 2021, 53, 332-341.	21.4	112
7	Dissecting the treatment-naïve ecosystem of human melanoma brain metastasis. <i>Cell</i> , 2022, 185, 2591-2608.e30.	28.9	62
8	A stochastic model for immunotherapy of cancer. <i>Scientific Reports</i> , 2016, 6, 24169.	3.3	42
9	A Preclinical Model of Malignant Peripheral Nerve Sheath Tumor-like Melanoma Is Characterized by Infiltrating Mast Cells. <i>Cancer Research</i> , 2016, 76, 251-263.	0.9	33
10	Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity. <i>Cancer Research</i> , 2020, 80, 798-810.	0.9	22
11	Tumor cell intrinsic Toll-like receptor 4 signaling promotes melanoma progression and metastatic dissemination. <i>International Journal of Cancer</i> , 2022, 150, 142-151.	5.1	7
12	The myeloid cell type I IFN system promotes antitumor immunity over pro-tumoral inflammation in cancer T cell therapy. <i>Clinical and Translational Immunology</i> , 2021, 10, e1276.	3.8	5
13	CXCR3: Here to stay to enhance cancer immunotherapy?. <i>EBioMedicine</i> , 2019, 49, 11-12.	6.1	3